TrialJournal of diabetes investigation2019

Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.

Hideka Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.